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Abstract
Huntington’s disease, like other neurodegenerative diseases, continues to lack an
effective cure. Current treatments that address early symptoms ultimately fail
Huntington’s disease patients and their families, with the disease typically being
fatal within 10–15 years from onset. Huntington’s disease is an inherited disorder
with motor and mental impairment, and is associated with the genetic expansion of
a CAG codon repeat encoding a polyglutamine-segment-containing protein called hun-
tingtin. These Huntington’s disease mutations cause misfolding and aggregation of
fragments of the mutant huntingtin protein, thereby likely contributing to disease tox-
icity through a combination of gain-of-toxic-function for the misfolded aggregates and
a loss of function from sequestration of huntingtin and other proteins. As with other
amyloid diseases, the mutant protein forms non-native fibrillar structures, which in
Huntington’s disease are found within patients’ neurons. The intracellular deposits
are associated with dysregulation of vital processes, and inter-neuronal transport of
aggregates may contribute to disease progression. However, a molecular understand-
ing of these aggregates and their detrimental effects has been frustrated by insuffi-
cient structural data on the misfolded protein state. In this review, we examine recent
developments in the structural biology of polyglutamine-expanded huntingtin frag-
ments, and especially the contributions enabled by advances in solid-state nuclear
magnetic resonance spectroscopy. We summarize and discuss our current structural
understanding of the huntingtin deposits and how this information furthers our understanding of the misfolding mechanism
and disease toxicity mechanisms.
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Introduction
Huntington’s disease (HD) is an inherited neurodegenera-
tive disease (NDD) in which the mutated protein under-
goes misfolding and aggregation in patients’ neuronal
cells. As such, it is one example of an expanding class of
protein misfolding and deposition diseases that include
Alzheimer’s disease (AD), Parkinson’s disease (PD), and
amyotrophic lateral sclerosis (ALS).1 The nature of the
disease-causing mutation makes HD the most well-
known example of a family of CAG repeat expansion dis-
orders. In each of these disorders, the mutation affects a
different gene with a naturally occurring CAG repeat,
which, when expanded past a disease-specific threshold
length, results in an age-dependent NDD (Figure 1(a)).
Impact statement
Many incurable neurodegenerative disor-
ders are associated with, and potentially
caused by, the amyloidogenic misfolding
and aggregation of proteins. Usually,
complex genetic and behavioral factors
dictate disease risk and age of onset. Due
to its principally mono-genic origin, which
strongly predicts the age-of-onset by the
extent of CAG repeat expansion,
Huntington’s disease (HD) presents a
unique opportunity to dissect the underly-
ing disease-causing processes in molecu-
lar detail. Yet, until recently, the mutant
huntingtin protein with its expanded poly-
glutamine domain has resisted structural
study at the atomic level. We present here
a review of recent developments in HD
structural biology, facilitated by break-
through data from solid-state NMR spec-
troscopy, electron microscopy, and com-
plementary methods. The misfolded
structures of the fibrillar proteins inform our
mechanistic understanding of the disease-
causing molecular processes in HD, other
CAG repeat expansion disorders, and,
more generally, protein deposition disease.
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On the protein level, this CAG repeat translates into a poly-
glutamine repeat, which in the wild-type proteins is typi-
cally between 10 and 35 glutamines long. Although the
mutated proteins are involved in divergent functional
roles, and include both soluble and membrane-bound pro-
teins, the diseases share common features. Six CAG repeat
expansion diseases are classified as spinocerebellar ataxias
(SCAs) with cerebellum atrophy leading to symptoms such
as poor hand or speech coordination, eye movement, or
cognitive impairment. Dentatorubral-pallidoluysian atro-
phy (DRPLA) is characterized by dementia, ataxia, and
choreoathetosis. Thus, a common phenotype seems inde-
pendent of the functions of the mutated protein, which
could be rationalized by commonalities in disease-
mechanisms driven by protein-based gain-of-toxic-
function in these and other protein misfolding diseases,1
rather than merely a loss of the native function. In these
NDDs, amyloid formation is a common hallmark, reflecting
protein aggregation accompanied by a conformational
change of the affected protein to a characteristic b-sheet
architecture.1 In AD and PD, our understanding of this
conformational transition was recently boosted by high-
resolution structures of protein filaments.2–4 Such structur-
al information on the misfolded protein assemblies has
proved more challenging to obtain in the case of HD,
but important recent progress will be examined in
this review.
HD mutant protein
First documented by George Huntington in 1872, HD
causes chorea and cognitive disruptions.5 It strikes adults
and rarely adolescents, but the latter are afflicted with
much harsher symptoms. The connection between HD
and mutation of the huntingtin (Htt) protein was identified
in the 1990s.6 The age of onset of HD and other polyglut-
amine expansion diseases is inversely dependent on the
length of the CAG repeat (Figure 1(a)). Therefore, HD
disease-risk is strongly predicted by its characteristic muta-
tion, in contrast to the genetic and environmental complex-
ities of AD and PD.
Wild-type Htt is a large multidomain protein with func-
tions in various cellular processes.7 Structurally, Htt is
prone to dynamic disorder with the most recognizable
folded domains forming so-called HEAT repeats. HEAT
repeats are a-helical domains found in a number of pro-
teins, whose names explain the HEATacronym: huntingtin,
elongation factor 3, A subunit of protein phosphatase 2A
and TOR1 signaling kinase. The large size of Htt and its
inherent disorder presented obstacles to structural determi-
nation until 2018 when cryo-electron microscopy (cryoEM)
was successfully applied to a complex of full-length
wild-type Htt stabilized by huntingtin-associated protein
40 (HAP40),8 yielding the Htt structure shown in Figure 1
(b). Nonetheless, segments constituting almost a quarter of
Htt remain invisible in this structure due to high local flex-
ibility, notably including the first exon of Htt (HttEx1) that
Figure 1. Genetic aspects of HD and other CAG repeat disorders. (a) Age of onset inversely correlates with the extent of expansion, for lengths beyond a disease-
specific threshold. The figure was adapted from Kuiper et al.9 with permission. (b) Wild-type Htt structure solved by cryoEM (PDB 6EZ8; Guo et al.8). (c) Color-coded
resolved and invisible domain segments from the Htt cryoEM structure, with the HttEx1 that contains the polyglutamine stretch enlarged below.
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features the polyglutamine segment mutated in HD
(Figure 1(c)).
This inherent disorder of HttEx1 (and its polyglutamine
segment) may be functionally relevant as the native role of
polyglutamine segments likely depends on their tendency
to be flexible and without well-defined secondary struc-
ture. Attempts at capturing a polyglutamine domain by
X-ray crystallography have yielded structures in which
the polyglutamine segment is either invisible or present
in a variety of structural states.10–12 Accordingly,
polyglutamine domains seem to act as semi-flexible linkers
that connect other functionally relevant domains.
Polyglutamine’s conformational ensemble may have
unique properties necessary for proper positioning of the
domains that flank it.13 Structural studies using fluores-
cence lifetime imaging microscopy detection of F€orster res-
onance energy transfer (FLIM-FRET) indicate a hinge-like
function of polyglutamine domains14,15 showing the impor-
tance of intramolecular proximity between N-terminal and
proline-rich domains. Others propose an innate ability for
interactions with specific protein partners based on a
glutamine-rich composition or multi-protein coiled–coil
formation.16,17
Aggregation by mutant Htt fragments
The flexible regions of Htt harbor a number of caspase
cleavage sites with apparent relevance to HD.18 Caspase 3
cleavage products formed in vitro are consistent with Htt
fragments in HD cerebellum, striatum and cortex, includ-
ing fragments that map onto HttEx1.19 A notable, but as yet
poorly understood aspect of the different-length Htt frag-
ments is that they cause different levels of toxicity. For
instance, in drosophila the HttEx1 fragments exert
particularly high toxicity.20 In human neurons, N-terminal
Htt fragments have been identified in neural intranuclear
inclusions (NIIs) and dystrophic neurites (DNs) (Figure 2
(a)), with their C-terminal counterparts in the cyto-
plasm.21,22 Remarkably, an HttEx1 fragment also forms
via erroneous splicing of the mutant protein.23
The findings described above led to many studies of
HttEx1 in model animals and neuronal cells, which com-
monly observe HD-like symptoms, neuronal degeneration,
and HttEx1 inclusions.24–26 A recent cryoEM tomography
study provided a view of the structures formed by aggre-
gated HttEx1 in a cellular context.27 A cluster of filamen-
tous structures is observed (Figure 2(b)), with individual
filaments resembling HttEx1 fibrils formed in vitro
(Figure 2(c) and (d)). Of potential disease-mechanistic rel-
evance, the fibrils interact with various subcellular organ-
elles, leading, for example, to deformation of the
endothelial reticulum (ER) membrane. Thus, lm-sized
puncta seen in fluorescence studies likely contain numer-
ous much smaller filaments. In isolation, these filaments are
hard or impossible to detect unless super-resolution optical
methods are applied.28,29 This distinction may in part
underlie the apparent disconnect between observable
aggregate load and neurotoxicity, given also that isolated
fibrils (assembled in vitro) are toxic to cells but may be
small enough to be missed in fluorescence assays
(Figure 2(g)).28,30–32
Polyglutamine segments have long been known to
undergo self-assembly in vitro. This aggregation propensity
depends on the repeat length,33,34 both in polyglutamine
peptides and in the context of HttEx1. Morphologically,
both polyglutamine peptides and HttEx1 form filamentous
assemblies (Figure 2), as seen by negative-stain
Figure 2. Mutant HttEx1 fibrils in vivo and in vitro. (a) Neuronal inclusions from HD patient; adapted from DiFiglia et al.21 with permission from AAAS. (b) 3D rendering of
tomographic EM showing the interaction zone between an inclusion body and cellular membranes in a HttQ97-transfected HeLa cell. ER membranes (red), ER-bound
ribosomes (green), HttQ97 fibrils (cyan), and vesicles inside the IB (white). Adapted from Bauerlein et al.27 with permission from Cell. (c) Annotated 3D EM tomogram of
Q51-HttEx1 fibrils (yellow) in presence of TRiC chaperones (blue/magenta). Adapted with permission from Shahmoradian et al.64 (d) Negative-stain EM of Q44-HttEx1
fibrils used for ssNMR study. Adapted from Hoop et al.56 (e) Q44-HttEx1 forms temperature-dependent polymorphs with different widths, which seed polyglutamine
protein aggregation (f) and cause neuronal toxicity (g). Panels (e–g) were adapted with permission from Lin et al.32
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transmission electron microscopy (TEM) or atomic force
microscopy (AFM).27,33,35,36 Crucially, the kinetics of self-
assembly are highly dependent on not only the polyglut-
amine length but also the segments flanking the polyglut-
amine (Figure 3(a)).37 The aggregation of HttEx1 is
dramatically more efficient than that of the corresponding
polyglutamine peptide,38,39 while the flanking regions also
affect the aggregates’ morphology and toxicity.37,40,41
The enhancement of aggregation has been traced to the
N-terminal segment preceding the polyglutamine domain,
commonly known as N17, NT17, or HttNT (Figure 1
(c)).38,41,42 Note that in vivo the first Met is likely removed
to yield a 16-residue HttNT starting with an acetylated Ala.
HttNT is critical for the trafficking and localization of Htt
and has a highly conserved primary sequence. In isolation,
HttNT is in a concentration-dependent equilibrium between
disordered monomers and a-helical multimers.38,43,44
Intermolecular interactions, including HttNT self-assembly,
stabilize amphipathic a-helical structure in HttNT.10,45,46
The C-terminal proline-rich domain (PRD) of HttEx1 great-
ly reduces the propensity for aggregation,47,48 but its effect
is outweighed by HttNT, when present (Figure 3(a)). PRD-
binding proteins, such as FE65,49 often do so by recognizing
the polyproline II (PPII) helical structure of the oligoproline
motifs. This same PPII propensity is thought to underpin
the aggregation inhibition.38,47,48
Clearly there is an important interplay in the unaggre-
gated protein between the behavior of the polyglutamine
domain and its respective flanking domains. Numerous
studies, both experimental and computational, have
probed this soluble structural ensemble50–52 but in the cur-




Shortly after the discovery that expanded polyglutamine
proteins result in the protein deposition of HD, models of
the aggregate structures were proposed. Perutz et al.53
advocated a structure of pleated antiparallel b-sheets, sta-
bilized by hydrogen bonds between the glutamine side
chain and backbone. Early X-ray structural studies of poly-
glutamine aggregates revealed a cross-b diffraction pattern
that is the hallmark of amyloids and amyloid-like struc-
tures.54 Similar data were obtained for both polyglutamine
peptides and fibrillar HttEx1,54 a finding reproduced by
later studies.55,56 The fiber diffraction data contain insuffi-
cient information to define a unique atomic-level structure
but did lead to a new structural hypothesis. First, Perutz
et al. 57 proposed a parallel b-sheet-based tubular fold,
offering a potential rationale for the HD expansion thresh-
old. However, a later report argued for an alternative expla-
nation of the same data, favoring an antiparallel rather than
parallel b-sheet structure, and featuring b-hairpin motifs.58
Note that the idea of b-hairpin formation during polyglut-
amine aggregation was invoked very early on by Perutz
et al.54 The antiparallel b-sheet architecture was supported
Figure 3. Mechanisms of aggregation. (a) Expanded polyglutamine without (Q30) and with (htt
NTQ30P10K2) Htt flanking regions attached show dramatically different
aggregation kinetics. Adapted from Sivanandam et al.77 with permission from the American Chemical Society. (b) Intrinsically disordered HttEx1 can aggregate via
both polyglutamine driven (top) and HttNT- driven mechanisms (bottom). (c) Both mechanisms yield products with the same ssNMR signals for the polyglutamine fibril
core structure (see Figure 4): spectra of Q44-HttEx1 and polyglutamine peptide, D2Q15K2. Adapted from Hoop et al.
56. (d) Length-dependent nucleus size data96–98
show that fast aggregation of long polyglutamine is facilitated by monomeric nucleation, likely involving b-hairpin formation. (e) Schematic free energy profile of fibril
formation and growth, for short and long polyglutamine, based on published nucleation and fiber elongation energy values.96,97,99,100
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by an independent X-ray study, which reported subtle var-
iations among different-length polyglutamine peptides and
proposed distinct structures with kinked side chains.55
Thus, while X-ray studies provided unambiguous evidence
of an amyloid-like architecture that was shared by aggre-
gated polyglutamine and HttEx1, they were unable to
resolve a unique atomic structure.
Various other techniques provided important clues
regarding the structure of aggregated polyglutamine.
Circular dichroism (CD), Fourier-transform infrared spec-
troscopy (FTIR), and UV resonance Raman (UVRR) spec-
troscopy indicated the formation of b-sheets, and
specifically antiparallel b-sheets.59–63 Notably, the Zanni
group combined multidimensional IR with isotopic label-
ing to observe b-hairpin structures in aggregated
K2Q24K2W.
61 As discussed below, b-hairpin motifs were
subsequently also detected in the expanded polyglutamine
segment of aggregated mutant HttEx1.32
Recent progress in HttEx1 fibril structure
The recent productive efforts toward a structural under-
standing of disease-relevant mutant HttEx1 aggregates
combined a number of biophysical methods. In isolation,
techniques like EM, nuclear magnetic resonance (NMR),
and electron spin resonance (ESR) provide incomplete
information, but together yield a compelling view of the
fibrils’ structure and dynamics. We have already intro-
duced various key contributions made by EM (Figure 2).
Moreover, EM and AFM have both revealed other
significant characteristics of HttEx1 fibrils, such as their
propensity to display branch points that is attributed to
surface-mediated secondary-nucleation events.35,64,65
However, unlike recent breakthrough studies of other pro-
tein filaments,3,4,66 EM thus far failed to resolve the atomic
structure of HttEx1 or polyglutamine aggregates, seeming-
ly due to the fibrils’ structural heterogeneity.27,64,67
NMR studies of fibrillar HttEx1
Liquid-state NMR studies have probed soluble ensembles
of polyglutamine-containing peptides and proteins.68–74
This technique excels at providing structural and dynamic
data on rapidly tumbling molecules in solution. However,
as soon as expanded polyglutamine proteins self-assemble,
they quickly form structures that no longer tumble fast
enough to be tractable by solution NMR. This is due to
the fact that immobilized or slowly tumbling molecules
yield very broad spectra with low intensities, thus prevent-
ing effective characterization. In recent years, modern
solid-state NMR (ssNMR) protocols and instrumentation
have made it feasible to study large and immobilized pro-
tein assemblies, even in presence of dynamic and static dis-
order,75,76 resulting in ssNMR becoming an essential tool
for amyloid protein research.2,75 Using magic angle spin-
ning (MAS), the immobilized large protein assemblies are
rapidly rotated in the magnetic field to generate high-
resolution ssNMR spectra, independent of assembly size.
The initial applications of ssNMR to polyglutamine-based
aggregates made less than a decade ago71,77 immediately
revealed a number of intriguing and important features.
First, despite dramatic differences in aggregation kinetics
or propensity, different labs consistently reported a highly
characteristic “signature” for the self-assembled misfolded
state of the polyglutamine stretch itself (Figures 3(c) and
4(a)). This ssNMR signature consistently combines highly
atypical resonance frequencies with two equally populated
sets of distinct NMR signals, in a unique combination that
is only seen in polyglutamine aggregates and not in any
other proteins studied by solution or solid-state NMR.78
The latter peak doubling arises even when a single residue
is labeled, indicating a structural heterogeneity on the
single-residue level.
Structural ssNMR measurements and mechanistic stud-
ies provide a compelling rationale for this surprising, but
reproducible, doubled ssNMR signature (see below;
Figures 3(c) and 4(a)). First, ssNMR measurements of back-
bone and side chain torsion angles confirmed that the
two signals derive from two distinct conformations
(Figure 4(b)).56 Inter-residue ssNMR correlations show
that each of these conformers is present in surprisingly
long, uninterrupted stretches.56,74,77–80 More specifically,
they form equal amounts of two distinct types of uninter-
rupted b-strands. The two strands differ in their side chain
torsion angles, but within each strand all residues have the
same backbone and side chain geometry (Figure 4(b)). Both
b-strands do share a 180 v2 angle – implying an extended
side chain structure56 akin to the steric zipper concept seen
in other amyloids.81 A recent ssNMR study that employed
dynamic nuclear polarization (DNP) allowed for the struc-
tural fingerprinting of unlabeled HttEx1 aggregates and
provided further evidence for their antiparallel b-sheet
assembly.56,82 In such an antiparallel arrangement, the
two ssNMR-revealed b-strand types appear capable of
inter-strand hydrogen bonding to each other (but not them-
selves). An assembled antiparallel b-sheet requires the
presence of equal amounts of the two complementary
b-strand geometries.83 Thereby, these findings provide a
rationale for the polyglutamine amyloid ssNMR signature
featuring equal amounts of the two corresponding sets of
ssNMR signals. All ssNMR studies of polyglutamine-based
aggregates with a single labeled residue show both signals
for that labeled residue.56,77,78,80,84 This points to a stochas-
tic assembly process in which any glutamine segment (or
residue) has a 50/50 chance of adopting either of the two
complementary b-strand motifs (Figure 4(c)56).
Polyglutamine length and the HD
disease threshold
Polyglutamine retains solubility up to a length of approxi-
mately seven residues,44,85 but peptides of eight or more
(well below the HD threshold) are routinely studied in
their aggregated state. Interestingly, polyglutamine pepti-
des with 15 to over 50 residues yield identical chemical shift
patterns by ssNMR that are indistinguishable from those of
HttEx1 fibrils’ amyloid core (Figures 3(c) and
4(a)).71,77,79,80,86 The ssNMR chemical shifts are very sensi-
tive to changes in structure and typically show clear differ-
ences between amyloid polymorphs with different core
structures.87 In ab initio calculations, the experimental
1588 Experimental Biology and Medicine Volume 244 December 2019
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ssNMR chemical shifts are inconsistent with the
pre-ssNMR structural models of polyglutamine discussed
above.56 Therefore, these ssNMR data are in apparent con-
tradiction with reports arguing for dramatic changes in
architecture between short and long polyglutamine
aggregates.55,88,89
Does this imply there is no length-dependent transition
in the misfolded structure or misfolding mechanism as a
rationale for the disease threshold? One potential rationale
has been proposed that integrates much of the available
structural and mechanistic data. Mixed-isotope ssNMR
experiments, reminiscent of the above-mentioned IR
study,61 identified intramolecularly hydrogen-bonded
b-hairpins in the amyloid core of Q44-HttEx1 fibrils
(Figure 4(c) and (d)).56 The weak intensity from non-
b-strand residues indicated that no more than a single
turn was present. This implied 20-residue strands consti-
tute the b-hairpin, which is reminiscent of the detection in a
prior ssNMR study of surprisingly long strand segments in
polyglutamine aggregates.71 Their study of a 15-residue
polyglutamine peptide with isotopic labels mid-peptide
did not reveal any turn structure signals. The Q15 peptides
featured a single b-strand per peptide, while the b-hairpin
Q44-HttEx1 fibrils contained two 20-residue strands
(Figure 4(d)). Thus, the propensity for b-hairpin formation
during polyglutamine (or HttEx1) aggregation would
depend on the polyglutamine expansion length, with
direct implications for the aggregation kinetics. In this
model, b-hairpin formation may be required to achieve a
sufficiently high aggregation propensity that cannot be
suppressed by the cellular protein homeostasis machinery
(under in vivo conditions). Interestingly, the currently avail-
able in vitro data (Figure 3(d)) point to the switch to mono-
meric nucleation occurring well below the typical disease
thresholds. This could imply that b-hairpin-mediated
aggregation is necessary but not sufficient for disease
onset. Alternatively, there may be an as-yet unknown
effect of environmental (cellular) factors modulating the
polyglutamine aggregation process in vivo, dictating
whether or not a particular polyglutamine length follows
a b-hairpin-driven aggregation process or not.
HttEx1 polymorphism
Various studies have noted that a particular HttEx1 protein
can adopt multiple types of misfolded or aggregated struc-
tures (e.g. Figure 2(e)).31,60 Such amyloid polymorphism is
also common in other disease-associated protein aggre-
gates.87 Early studies suggested that HttEx1 polymorphism
stems from an architectural change of the polyglutamine
stretch.60 However, ssNMR experiments consistently
report identical signatures for the polyglutamine stretch,
with polymorph-dependent differences localized to the
non-amyloid flanking segments. This suggests that expand-
ed polyglutamine forms a reproducible protofilament
structure that can co-assemble into different
supramolecular architectures, stabilized by variable
flanking region interactions.32 Conceptually analogous
“supramolecular polymorphs”3 have subsequently
been described in several other disease-related amyloids,
indicating that this may be a more general
phenomenon.3,4,66,90,91
Both ssNMR and ESR studies have been instrumental in
probing the fate of the flanking regions in HttEx1 post-
aggregation.32,45,74,77,79,80,84,86 In contrast with the rigid
and well-structured polyglutamine motif, both flanking
segments are consistently found to display significant
dynamics. The greatest flexibility is associated with the
C-terminal end of HttEx1, which usually retains similar
Figure 4. SSNMR structural studies of misfolded fibrils. (a) Fibrillar polyglutamine gives an identical ssNMR signature, whether in Q44-HttEx1 fibrils (top), Q46-HttEx1
fibrils (bottom), or polyglutamine peptides with 15 or 30 glutamines. Data from Lin et al.32 and Sivanandam et al.77 Data for Q46-HttEx1 were adapted with permission
from Isas et al.79 copyright 2015 American Chemical Society. (b) Tailored ssNMR dihedral angle measurements probe the polyglutamine core structure, and reveal two
differently structured b-strand types (adapted from Hoop et al.56). (c) A stochastic assembly process of the alternating b-strand structures explains the ssNMR spectral
signature of polyglutamine amyloid. Adapted with permission from Hoop et al.56 (d) Architecture of mutant HttEx1 fibrils derived from ssNMR and EM constraints. (e)
SSNMR relaxation measurements show dynamic changes in the solvent-exposed HttNT a-helical segment upon solvent freezing. Adapted from Hoop et al.,80 with
permission from the American Chemical Society. (f) Schematic illustration of flanking-domain interactions enabling higher order assembly of the wider HttEx1 fibril
polymorphs shown in Figure 2(e). Panels (d) and (f) are adapted with permission from Lin et al.32 (A color version of this figure is available in the online journal.)
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dynamics and accessibility before and after aggrega-
tion.32,79,92,93 Approaching the rigid polyglutamine amy-
loid core, the PRD becomes increasingly rigid,
presumably due to intermolecular interactions.32,79,92,93
The HttNT flanking segment also has increased mobility
and solvent accessibility (Figure 4(d) and (e)) relative to
the polyglutamine fibril core.32,77,79,80 The reported dynam-
ics and secondary structure of the HttNT varied among dif-
ferent studies, which may relate to a combination of fibril
polymorphism, differences in protein constructs employed,
and different fibril formation protocols. In our own
work,32,77,84 ssNMR studies of HttNT in the fibrils consis-
tently point to an a-helical conformation and a partial,
though incomplete, immobilization (Figure 4(e)), likely
facilitated by dense packing of the flanking segments on
the fibril surface (Figure 4(d)).
When comparing different HttEx1 polymorphs (Figure 2
(e)), ssNMR studies show clear differences in the dynamics
and solvent accessibility of the flanking segments.32,93
Antibodies that recognize specific parts of the HttEx1
sequence also bind differently.32 The variable flanking seg-
ment exposure in HttEx1 polymorphs points to a mecha-
nism for stabilizing the supramolecular polymorphs
(Figure 4(f)), leading to the distinct fiber widths observed
by EM (Figure 2(e)). These differences in burial or exposure
of the flanking sequences should also modulate the biolog-
ical (e.g. toxic) activity of the misfolded protein. For exam-
ple, exposed and dynamic79,80,92 HttNT are implicated in
membrane interactions, and their accessibility will affect
the filaments’ ability to bind cellular membranes.27,94,95
The flanking segments’ varying ability to engage with bio-
logical membranes, chaperones, and other protein binding
partners will have direct relevance for various pathogen-
ic mechanisms.
Biological and mechanistic implications
The increased availability of structural information has
greatly improved our understanding of the mechanisms
by which polyglutamine proteins misfold, aggregate, and
contribute to disease. Like other amyloidogenic processes,
polyglutamine aggregation is nucleation driven. The nucle-
ation event is the rate-limiting step with a positive free
energy (DG) and very small equilibrium constant for nucle-
us formation (Kn*)
96 (Figure 3(e)). Once a minimal nucleus
is formed, the elongation process is thermodynamically
favorable and spontaneous.99,101 For polyglutamine, Kn*
increases with longer repeat lengths, leading to ever
faster aggregation of proteins with longer polyglutamine
repeats.96 Thus, Htt fragments with very long glutamine
repeats nucleate more quickly than those with short
repeats. Why does Kn* show this length dependence, and
which conformation can lower the free energy of nuclei for
longer repeat lengths? The size of the critical nucleus
depends on polyglutamine length (Figure 3(d))100,101:
although short polyglutamines aggregate, they require a
multimeric nucleation event. The rate-limiting step for
long polyglutamine manifests instead as a monomeric
event.100,101 Various lines of evidence support the idea
that monomeric nucleation reflects the formation of a
b-hairpin within the expanded polyglutamine monomer.
Structural studies detect b-hairpin structures in the end-
product of aggregated polyglutamine and Q44-
HttEx1.56,61 Moreover, b-hairpin-favoring mutations accel-
erate aggregation kinetics and increase fiber stabilities,
without changing the characteristic polyglutamine
ssNMR signature.78
Molecular dynamics (MD) simulation studies can exam-
ine transient events and dynamic processes that are hard to
probe experimentally. Given the focus on this review, we
refer readers to other recent articles.50,51 We do note an
interesting set of MD studies that probed polyglutamine
folds that may be compatible with the noted “monomeric”
mechanism,100,102 since they favored b-hairpin motifs over
less stable b-nanotube or b-pseudohelix conformations.
As noted above, all polyglutamine aggregate studied by
ssNMR to date share a common characteristic ssNMR sig-
nature. One intriguing possibility is that this reflects a
common core structure that may extend to all polyglut-
amine proteins associated with disease and that all the
expanded-polyglutamine proteins aggregate via an analo-
gous misfolding pathway. The different disease thresholds
may relate to the impact of protein context (i.e. flanking
domains) on the propensity for the polyglutamine region
to adopt an elongation-capable b-hairpin. In HD, the flank-
ing regions are dynamically disordered, allowing the poly-
glutamine segment termini to readily approach each other.
Yet, in other polyglutamine proteins, combinations of steric
interactions and/or electrostatic repulsion of the flanking
domains may hinder b-hairpin formation. On the other
hand, the protein fold of the a1 subunit of the neuronal
P/Q-type voltage-gated calcium channel (associated with
SCA6 disease103,104) may place its polyglutamine stretch in
a conformation that encourages b-hairpin formation. This
could rationalize the reduced threshold seen in SCA6, com-
pared to the other polyglutamine expansion diseases104
(Figure 1(a)). Further structural and mechanistic studies
are needed to test these proposals.
Oligomerization
Some reports claim that long polyglutamine peptides form
small spherical oligomers (dimers and trimers) that coexist
with larger ones in solution.89 However, other studies offer
compelling evidence that polyglutamine de novo aggrega-
tion proceeds without formation of defined oligomers.96,97
There is more evidence for the formation of prefibrillar olig-
omeric assemblies for expanded HttEx1.105–108 In cells,
wild-type HttEx1 can undergo a type of liquid–liquid
phase separation, while polyglutamine-expanded HttEx1
assembles into more compact irreversible inclusions.109
When studied structurally, HttEx1 oligomers generally
appear to be a-helical, rather than b-sheet-rich like Ab
oligomers.38,44,77,110 This helical structure is stabilized by
bundling of a-helical HttNT, with the a-helical structure
likely extending into the initial parts of the
polyglutamine.44,77
The above differs notably from the extensively studied
oligomers formed by the AD Ab peptide. Ab oligomers
feature antiparallel b-sheet structures, which are distinct
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from the in-register parallel b-sheet fibrils, and which by
many are proposed to reflect b-hairpins. An intriguing pos-
sibility is that b-hairpin formation may similarly occur
during polyglutamine and Ab aggregation, but that
(unlike polyglutamine) the Ab b-hairpin motif is not
accommodated in the filamentous structure, instead
becoming trapped in the semi-stable oligomeric
intermediates.
The role of aggregates in disease
There is an ongoing debate whether Htt-related aggregates
in the brain are cytotoxic and cause disease development,
or the toxicity comes from other species, such as soluble
oligomers or even misfolded monomers. Some studies
showed no correlation between Htt aggregates and cell tox-
icity.111,112 On the other hand, many studies have shown
toxic effects of HttEx1 or polyglutamine aggregates on neu-
ronal cells.60,113–115 Various rationales have been proposed
to unify these seemingly contradictory findings, and we
will discuss some with an eye on the current knowledge
of HttEx1 aggregate structure. First, as noted above,
fluorescence-based assays commonly used in evaluating
aggregate load may not reliably measure sub-diffraction
sized protein deposits. As illustrated in Figure 2, individual
filaments have widths on the nm-scale and are thus orders
of magnitude smaller than visible inclusions. Thus, cells
lacking lm-sized puncta may nonetheless contain signifi-
cant amounts of protein filaments. Second, different poly-
morphs can exhibit substantially different levels of toxicity.
The toxicity of polyglutamine proteins is dependent of the
flanking sequences, protein–protein interactions, and fibril
polymorphism.40,60 For example, in a mouse that expressed
a truncated fragment of expanded Htt that is longer
than HttEx1 (shortstop mouse), the existence of neural
inclusions did not lead to neural abnormalities or
degeneration.112
This also raises the fundamental question of the mecha-
nism of toxicity. In our view, this issue remains largely
unresolved. One mechanism specific to polyglutamine pro-
teins is the recruitment or sequestration of other proteins
featuring polyglutamine repeats by the aggregates, which
similarly affects wild-type and expanded polyglutamine
proteins. Thus, the cellular concentrations of essential pro-
teins could be lowered to the point of dysfunction or tox-
icity. A study that attempted to test this mechanism using
D-amino-acid polyglutamine aggregates found that even
these fibrils induced toxicity in PC12 neuronal cells, but
also offered a potential structural rationale by which
observed recruitment could cross the chiral barrier.115
Aggregated Htt is also thought to impair intracellular traf-
ficking into organelles such as the mitochondria and nucle-
us, potentially by interacting with the import/export
protein machinery. Moreover, polyglutamine protein inclu-
sions sequester many non-polyglutamine proteins, includ-
ing components of the protein quality control machinery.
Thus, fibrils are known to have various detrimental effects.
There is also a growing interest in the finding that Htt fibers
are able to propagate from one cell to another, enabling
disease propagation via a prion-like process.116,117 This
phenomenon requires the fibers to have conformations
amenable to them crossing cellular membranes and seed-
ing the self-assembly of other proteins in nearby cells. In
other words, the polymorphism of Htt-derived aggregates,
which we are only just beginning to understand, can likely
dramatically alter their biological behavior and pathogenic
effects in a way that is orthogonal to the apparent aggre-
gate load.
Counteracting and controlling protein
aggregation
Nature has deployed cellular protection mechanisms to
counteract disease-causing protein misfolding and aggre-
gation. Molecular chaperones refold misfolded proteins
and prevent pathogenic protein aggregation.118–120
Chaperones such as TRiC, DNAJB6 and DNAJB8 have
been shown to inhibit Htt aggregation.64,121,122 The pro-
posed molecular mechanisms by which these chaperones
act are mirrored in the abovementioned structural data for
the aggregates. TRiC binds the a-helical HttNT that was
detected by ssNMR in the HttEx1 fibrils, while the men-
tioned DNAJ co-chaperones appear to inhibit primary
nucleation by recognizing b-hairpins. Thus, the fiber struc-
tures mirror the very structural features that can be tar-
geted for the inhibition or modulation of aggregation.
Along similar lines, post-translational modifications
(PTMs) offer a mechanism for modulating disease risk
and aggregation. Phosphorylation of HttNT is dependent
on the glutamine repeat length123,9 and changes aggrega-
tion and toxicity.84,125 The clustering of the PTMs’ repulsive
charges in the densely packed HttNT in misfolded Htt
(Figure 4) leads to a destabilization that enhances the neu-
rons’ ability to target and clear the Htt aggregates. Thus,
insights into the structures of disease-associated protein
deposits can direct efforts to design novel or enhanced
treatment strategies. One critical component in such efforts
will be the delineation of the structural variables (e.g.
supramolecular architecture and/or exposure of flanking
domains) that most strongly predict biological functions
such as neuronal toxicity, membrane interactions, and
inter-neuron propagation. We hope that progress made in
understanding HD may also inform our understanding
(and treatment) of more complex NDDs like AD, PD
and ALS.
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